Elsevier

Neuropharmacology

Volume 46, Issue 7, June 2004, Pages 954-965
Neuropharmacology

Cannabinoids prevent the acute hyperthermia and partially protect against the 5-HT depleting effects of MDMA (“Ecstasy”) in rats

https://doi.org/10.1016/j.neuropharm.2004.01.002Get rights and content

Abstract

Cannabinoid–MDMA interactions were examined in male Wistar rats. MDMA (4×5 mg/kg or 2×10 mg/kg over 4 h on each of 2 days) was administered with or without Δ9-tetrahydrocannabinol (THC) (4×2.5 mg/kg), the synthetic cannabinoid receptor agonist CP 55,940 (2×0.1 or 0.2 mg/kg) or the cannabinoid receptor antagonist SR 141716 (2×5 mg/kg). Co-administered Δ9-THC and CP 55,940 but not SR 141716 prevented MDMA-induced hyperthermia, causing a powerful hypothermia. Co-administered Δ9-THC, CP 55,940 and SR 141716 all tended to decrease MDMA-induced hyperactivity. Co-administered Δ9-THC provided protection against the long-term increases in anxiety seen in the emergence test, but not the social interaction test, 6 weeks after MDMA treatment. Co-administered Δ9-THC and CP 55,940, but not SR 141716, partly prevented the long-term 5-HT and 5-HIAA depletion caused by MDMA in various brain regions. SR 141716 administered with CP 55,940 and MDMA prevented the hypothermic response to the CP 55,940/MDMA combination but did not alter the CP 55,940 attenuation of MDMA-induced 5-HT depletion. These results suggest a partial protective effect of co-administered cannabinoid receptor agonists on MDMA-induced 5-HT depletion and long-term anxiety. This action appears to operate independently of cannabinoid CB1 receptors.

Introduction

3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) is a widely used illicit drug. The possible adverse effects of MDMA use are a matter of some considerable concern. In laboratory animals, MDMA causes 5-HT nerve terminal degeneration with a concomitant reduction in brain 5-HT content (for reviews see Ricaurte et al., 2000, Green et al., 2003). Human MDMA users also exhibit several effects consistent with 5-HT depletion (Boot et al., 2000, McCann et al., 1998, Parrott, 2001, Reneman et al., 2001) and this may be linked to a number of adverse psychological effects including anxiety, depression and impaired cognition (Morgan, 2000; Parrott, 2001). However, a specific causal relationship between MDMA use and psychological dysfunction is difficult to demonstrate. This is because of the polydrug use that is typical of human MDMA users and the possibility of pre-existing psychopathology in users (Cole et al., 2002, Croft et al., 2001).

Brief exposure to MDMA in rats causes a long-lasting syndrome consisting of greater anxiety-like behaviours, impaired memory and depressive-like symptoms (Bull et al., 2003, Fone et al., 2002, Gurtman et al., 2002, McGregor et al., 2003a, McGregor et al., 2003b, Morley et al., 2001). Such effects are consistent with human reports and may reflect MDMA-induced 5-HT depletion and/or alterations in the density of 5-HT receptors and transporters (McGregor et al., 2003a, McGregor et al., 2003b).

The neurotoxic effects of MDMA are modulated by dose, frequency and route of administration (O’Shea et al., 1998, Ricaurte et al., 2000) as well as the hyperthermic action of the drug (Malberg et al., 1996, Malberg and Seiden, 1998; but see also McGregor et al., 2003b). Interventions that prevent MDMA-induced hyperthermia protect against the neurotoxic effects of the drug (Colado et al., 1998, Malberg et al., 1996, O’Shea et al., 2001). Drugs with antioxidant properties also attenuate the neurotoxic effects of MDMA (Colado and Green, 1995, Colado et al., 1997, Shankaran et al., 2001).

The drug most commonly taken with MDMA in human users is cannabis. More than 90% of ecstasy users take cannabis regularly (Siliquini et al., 2001, Topp et al., 1999). Cannabis is frequently used to mitigate the MDMA “comedown” (Winstock et al., 2001) but is also commonly used before and during dance parties at which MDMA is taken (Boys et al., 1997).

The primary psychoactive constituent of cannabis, Δ9-tetrahydrocannabinol (THC), and synthetic cannabinoid receptor agonists such as CP 55,940, cause hypothermia (Arnold et al., 2001, Fennessy and Taylor, 1978, Pryor et al., 1978). Recent research also indicates that these cannabinoids have antioxidant properties (Hampson et al., 1998, Leker et al., 1999, Marsicano et al., 2002, Nagayama et al., 1999, Shohami and Mechoulam, 2000). This suggests that co-administered cannabinoids might modulate the long-term neurotoxic properties of MDMA either through a hypothermic action, an antioxidant action, or both.

The present study addressed this possibility. Firstly, the effects of co-administered THC on the acute hyperthermia and long-term behavioural and neural effects of MDMA were investigated. Then the possible neuroprotective effects arising from the co-administration of the synthetic cannabinoid CP 55,940 and the cannabinoid CB1 receptor antagonist SR 141716 were examined.

Section snippets

Animals

Inbred male albino Wistar rats were used in all experiments. They were housed in large plastic tubs in groups of 6–8 per cage in a temperature-controlled environment (mean 22 °C) with food and water freely available. A 12 h reversed light cycle was in operation with lights off at 8:30 am. Testing took place during the dark cycle. All experimental procedures were carried out in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No.

Body temperature

Body temperature changes on the 2 days of drug administration are depicted in Fig. 1. For day 1, ANOVA revealed significant differences between groups for highest (F(3,48)=12.10, P<0.0001) and lowest (F(3,48)=6.73, P<0.001) body temperature recorded (expressed as change from pre-drug baseline). Similar results were obtained on day 2 of drug treatment (F(3,48)=16.43, P<0.0001) and (F(3,48)=23.69, P<0.0001), respectively. Post-hoc analyses (Fig. 1) revealed a significant hyperthermic effect of

Discussion

The present study indicates that co-administration of the main psychoactive constituent of cannabis (THC) or the synthetic cannabinoid CP 55,940 prevents the hyperthermia and partially attenuates the long-term 5-HT depletion produced by MDMA. Furthermore, these results indicate that the CB1 receptor antagonist SR 141716, while reversing cannabinoid agonist effects on MDMA-induced hyperthermia, does not prevent the prophylactic effects of cannabinoid agonists on MDMA-induced 5-HT depletion.

MDMA

Acknowledgements

This work was supported by a National Health and Medical Research Council grant to ISM and GEH and an Australian Research Council grant to ISM and PEM. Kirsten Morley is the recipient of an Australian Postgraduate Award.

References (46)

  • K.C. Morley et al.

    (+/−)-3,4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’) increases social interaction in rats

    European Journal of Pharmacology

    (2000)
  • K.C. Morley et al.

    Increased anxiety and impaired memory in rats 3 months after administration of 3,4-methylenedioxymethamphetamine (“Ecstasy”)

    European Journal of Pharmacology

    (2001)
  • C.S. Norwood et al.

    Pre-exposure to the cannabinoid receptor agonist CP 55,940 enhances morphine behavioral sensitization and alters morphine self-administration in Lewis rats

    European Journal of Pharmacology

    (2003)
  • E. O’Shea et al.

    The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA (Ecstasy)

    Neuropharmacology

    (1998)
  • E. O’Shea et al.

    Effect of GBR12909 and fluoxetine on the acute and long term changes induced by MDMA (‘Ecstasy’) on the 5-HT and dopamine concentrations in mouse brain

    Neuropharmacology

    (2001)
  • G.T. Pryor et al.

    Interactions of delta9-tetrahydrocannabinol with d-amphetamine, cocaine, and nicotine in rats

    Pharmacology, Biochemistry and Behavior

    (1978)
  • L. Reneman et al.

    Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (Ecstasy) on brain serotonin neurons

    Lancet

    (2001)
  • G.A. Ricaurte et al.

    Toxicodynamics and long-term toxicity of the recreational drug, 3,4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’)

    Toxicology Letters

    (2000)
  • R. Siliquini et al.

    Patterns of drug use among young men in Piedmont (Italy)

    Drug and Alcohol Dependence

    (2001)
  • L. Topp et al.

    Ecstasy use in Australia: patterns of use and associated harm

    Drug and Alcohol Dependence

    (1999)
  • A.R. Winstock et al.

    Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK

    Drug and Alcohol Dependence

    (2001)
  • A. Boys et al.

    Polydrug use at raves by a Western Australian sample

    Drug and Alcohol Review

    (1997)
  • Y. Chen et al.

    Cannabinoids protect cells from oxidative cell death: a receptor-independent mechanism

    Journal of Experimental Therapeutics

    (2000)
  • Cited by (50)

    • NMDA receptor adjusted co-administration of ecstasy and cannabinoid receptor-1 agonist in the amygdala via stimulation of BDNF/Trk-B/CREB pathway in adult male rats

      2017, Brain Research Bulletin
      Citation Excerpt :

      Also, many investigations showed neurotoxic effects of MDMA and CB1 receptor agonist on memory and cognition behavior as well as neuronal loss (Lopez-Rodriguez et al., 2014; Petschner et al., 2013; Rodriguez-Arias et al., 2013). In contrast, Morley and co-workers found that co-administration of MDMA and CB agonist had protective effects on locomotion and social interaction; they suggested that cannabinoids act through CB1-independent pathway (Morley et al., 2004). The co-administration effect of MDMA and CB1 receptor agonist has been widely researched on many physiological parameters such as behavioral and molecular factors (Daza-Losada et al., 2011; Petschner et al., 2013; Schulz et al., 2013), but there are not enough data on MDMA and ACPA effects on brain electrophysiology and molecular changes.

    • Cannabis and the Use of Amphetamine-Like Substances

      2017, Handbook of Cannabis and Related Pathologies: Biology, Pharmacology, Diagnosis, and Treatment
    • Neuroimaging in moderate MDMA use: A systematic review

      2016, Neuroscience and Biobehavioral Reviews
      Citation Excerpt :

      Co-consumption of other substances may increase adverse effects caused by MDMA, as the use of other drugs, such as nicotine, alcohol, cocaine and other amphetamines, may lead to pharmacological interactions and additive effects (Carvalho et al., 2012). These effects can also be protective, as cannabis may antagonise (Morley et al., 2004; Touriño et al., 2010) the hyperthermic effects of MDMA (Freedman et al., 2005), which are supposed to increase MDMA's neurotoxicity (Capela et al., 2009). In general, there is considerable uncertainty about the extent of use and potential influence of other drugs in the studies discussed in this review.

    • Chronic co-administration of the cannabinoid receptor agonist WIN55,212-2 during puberty or adulthood reverses 3,4 methylenedioxymetamphetamine (MDMA)-induced deficits in recognition memory but not in effort-based decision making

      2013, Pharmacology Biochemistry and Behavior
      Citation Excerpt :

      The significantly increased number of rearings of all pubertally treated rats probably reflects age-dependent, rather than treatment-related, differences (cf. adults). Adding to the well-established effect of hyperactivity after acute MDMA treatment (Green et al., 2003), and amelioration thereof by cannabinoid agents (Morley et al., 2004), our results indicate that chronic administration of MDMA does not result in long-term hyperactivity. With respect to body weight, adult MDMA animals kept on a restricted feeding regime weighed slightly more than controls and WIN-treated animals, probably because they were kept under restricted feeding conditions in one cage with MDMA + WIN animals, which had a reduced food intake, so that MDMA-treated rats were left with more available food.

    • Methamphetamine-induced dopamine terminal deficits in the nucleus accumbens are exacerbated by reward-associated cues and attenuated by CB1 receptor antagonism

      2012, Neuropharmacology
      Citation Excerpt :

      Co-administration of rimonabant does not prevent hyperthermia from MDMA (Morley et al., 2004), a substituted amphetamine (Cadet et al., 2007) with similar hyperthermic, behavioral, neurotoxic and neurochemical effects as METH (Fantegrossi et al., 2008; Gough et al., 2002). Moreover, CB1 receptor agonism is associated with hypothermia (Morley et al., 2004; Touriño et al., 2010) and it is thus unlikely that CB1 receptor blockade also induces hypothermia, which might otherwise explain the attenuation of METH-induced dopamine depletion associated with rimonabant pretreatment. Although antioxidants mitigate METH-induced monoaminergic depletions (De Vito and Wagner, 1989; Hashimoto et al., 2004), rimonabant lacks antioxidant activity (Tsvetanova et al., 2006).

    View all citing articles on Scopus
    View full text